These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
165 related articles for article (PubMed ID: 20626228)
1. Clinical evaluation of natalizumab for formulary consideration. Bivins A; Hou K; Ayesu N; Ellsworth B; Montenegro S; Tu X; Boyle C; Dowling T; Shaya FT Expert Opin Biol Ther; 2010 Aug; 10(8):1279-87. PubMed ID: 20626228 [TBL] [Abstract][Full Text] [Related]
2. Natalizumab for the treatment of multiple sclerosis and Crohn's disease. Keeley KA; Rivey MP; Allington DR Ann Pharmacother; 2005 Nov; 39(11):1833-43. PubMed ID: 16219898 [TBL] [Abstract][Full Text] [Related]
3. The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL. Calabresi PA; Giovannoni G; Confavreux C; Galetta SL; Havrdova E; Hutchinson M; Kappos L; Miller DH; O'Connor PW; Phillips JT; Polman CH; Radue EW; Rudick RA; Stuart WH; Lublin FD; Wajgt A; Weinstock-Guttman B; Wynn DR; Lynn F; Panzara MA; Neurology; 2007 Oct; 69(14):1391-403. PubMed ID: 17761550 [TBL] [Abstract][Full Text] [Related]
4. Natalizumab: pharmacology, clinical efficacy and safety in the treatment of patients with Crohn's disease. Ko HH; Bressler B Expert Rev Gastroenterol Hepatol; 2007 Oct; 1(1):29-39. PubMed ID: 19072431 [TBL] [Abstract][Full Text] [Related]
6. Natalizumab reduces visual loss in patients with relapsing multiple sclerosis. Balcer LJ; Galetta SL; Calabresi PA; Confavreux C; Giovannoni G; Havrdova E; Hutchinson M; Kappos L; Lublin FD; Miller DH; O'Connor PW; Phillips JT; Polman CH; Radue EW; Rudick RA; Stuart WH; Wajgt A; Weinstock-Guttman B; Wynn DR; Lynn F; Panzara MA Neurology; 2007 Apr; 68(16):1299-304. PubMed ID: 17438220 [TBL] [Abstract][Full Text] [Related]
7. The cost effectiveness and budget impact of natalizumab for formulary inclusion. Bakhshai J; Bleu-Lainé R; Jung M; Lim J; Reyes C; Sun L; Rochester C; Shaya FT J Med Econ; 2010 Mar; 13(1):63-9. PubMed ID: 20028199 [TBL] [Abstract][Full Text] [Related]
8. The role of natalizumab in the treatment of multiple sclerosis. Coyle PK Am J Manag Care; 2010 Jun; 16(6 Suppl):S164-70. PubMed ID: 20615052 [TBL] [Abstract][Full Text] [Related]
9. Assessment: the use of natalizumab (Tysabri) for the treatment of multiple sclerosis (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Goodin DS; Cohen BA; O'Connor P; Kappos L; Stevens JC; Neurology; 2008 Sep; 71(10):766-73. PubMed ID: 18765653 [TBL] [Abstract][Full Text] [Related]
10. Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial. Targan SR; Feagan BG; Fedorak RN; Lashner BA; Panaccione R; Present DH; Spehlmann ME; Rutgeerts PJ; Tulassay Z; Volfova M; Wolf DC; Hernandez C; Bornstein J; Sandborn WJ; Gastroenterology; 2007 May; 132(5):1672-83. PubMed ID: 17484865 [TBL] [Abstract][Full Text] [Related]
11. Assessing disability progression with the Multiple Sclerosis Functional Composite. Rudick RA; Polman CH; Cohen JA; Walton MK; Miller AE; Confavreux C; Lublin FD; Hutchinson M; O'Connor PW; Schwid SR; Balcer LJ; Lynn F; Panzara MA; Sandrock AW Mult Scler; 2009 Aug; 15(8):984-97. PubMed ID: 19667023 [TBL] [Abstract][Full Text] [Related]
12. Natalizumab (Tysabri) returns. Med Lett Drugs Ther; 2006 Sep; 48(1243):76. PubMed ID: 16977289 [No Abstract] [Full Text] [Related]
16. Cost effectiveness and budget impact of natalizumab in patients with relapsing multiple sclerosis. Chiao E; Meyer K Curr Med Res Opin; 2009 Jun; 25(6):1445-54. PubMed ID: 19422279 [TBL] [Abstract][Full Text] [Related]
17. Paradoxically aggressive multiple sclerosis in the face of natalizumab therapy. Berger JR Mult Scler; 2008 Jun; 14(5):708-10. PubMed ID: 18566035 [TBL] [Abstract][Full Text] [Related]
18. [Natalizumab in the treatment of multiple sclerosis]. Horga A; Horga de la Parte JF Rev Neurol; 2007 Sep 1-15; 45(5):293-303. PubMed ID: 17876741 [TBL] [Abstract][Full Text] [Related]
19. Natalizumab reduces clinical and MRI activity in multiple sclerosis patients with high disease activity: results from a multicenter study in Switzerland. Putzki N; Yaldizli O; Bühler R; Schwegler G; Curtius D; Tettenborn B Eur Neurol; 2010; 63(2):101-6. PubMed ID: 20090344 [TBL] [Abstract][Full Text] [Related]